These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37804290)

  • 41. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR.
    Escaned J; Cao D; Baber U; Nicolas J; Sartori S; Zhang Z; Dangas G; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dudek D; Gibson M; Gil R; Huber K; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta S; Moliterno DJ; Ohman EM; Oldroyd KG; Sardella G; Sharma SK; Shlofmitz R; Weisz G; Witzenbichler B; Pocock S; Mehran R
    Eur Heart J; 2021 Dec; 42(45):4624-4634. PubMed ID: 34662382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.
    Bavishi C; Koulova A; Bangalore S; Sawant A; Chatterjee S; Ather S; Valencia J; Sarafoff N; Rubboli A; Airaksinen JK; Lip GY; Tamis-Holland JE
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):E12-22. PubMed ID: 26354765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.
    Pivato CA; Reimers B; Testa L; Pacchioni A; Briguori C; Musto C; Esposito G; Piccolo R; Lucisano L; De Luca L; Conrotto F; De Marco A; Franzone A; Presbitero P; Ferrante G; Condorelli G; Paradies V; Sardella G; Indolfi C; Condorelli G; Stefanini GG
    J Am Heart Assoc; 2022 Mar; 11(6):e023454. PubMed ID: 35114814
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
    Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
    BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Int J Clin Pract; 2021 Jul; 75(7):e13938. PubMed ID: 33341109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
    Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
    Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.
    Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
    Thromb Res; 2022 Jan; 209():16-22. PubMed ID: 34844044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.
    Smits PC; Frigoli E; Vranckx P; Ozaki Y; Morice MC; Chevalier B; Onuma Y; Windecker S; Tonino PAL; Roffi M; Lesiak M; Mahfoud F; Bartunek J; Hildick-Smith D; Colombo A; Stankovic G; Iñiguez A; Schultz C; Kornowski R; Ong PJL; Alasnag M; Rodriguez AE; Paradies V; Kala P; Kedev S; Al Mafragi A; Dewilde W; Heg D; Valgimigli M;
    J Am Coll Cardiol; 2022 Sep; 80(13):1220-1237. PubMed ID: 36137672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study.
    Wang HY; Dou KF; Guan C; Xie L; Huang Y; Zhang R; Yang W; Wu Y; Yang Y; Qiao S; Gao R; Xu B
    Circ Cardiovasc Interv; 2022 Jun; 15(6):e011536. PubMed ID: 35582961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
    Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
    Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Benefits and risks of prolonged dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent in patients with stable coronary artery disease and diabetes].
    Cui KY; Yin D; Feng L; Zhu CG; Song WH; Wang HJ; Jia L; Zhang D; Yuan S; Wu SY; He JN; Qiao Z; Dou KF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):458-465. PubMed ID: 35589594
    [No Abstract]   [Full Text] [Related]  

  • 60. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.